Problems monitoring response in multiple myeloma

Collins, Conor D

doi:10.1102/1470-7330.2005.0033

Cited by 28 publications

(13 citation statements)

References 87 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Although MM is relatively rare, it is the second most prevalent hematological cancer after non-Hodgkin’s lymphoma (Collins, 2005), accounting for 114,251 new cases and 80,015 deaths each year (WHO, 2012). CXCR4 overexpression was detected in 43.2% of MM patients (Bao et al, 2013).…”

Section: Role Of Cxcr4 In Cancermentioning

confidence: 99%

The Intricate Role of CXCR4 in Cancer

Chatterjee

Azad

Nimmagadda

2014

Advances in Cancer Research

551

546

View full text Add to dashboard Cite

Chemokines mediate numerous physiological and pathological processes related primarily to cell homing and migration. The chemokine CXCL12, also known as stromal cell-derived factor-1, binds the G-protein-coupled receptor CXCR4, which, through multiple divergent pathways, leads to chemotaxis, enhanced intracellular calcium, cell adhesion, survival, proliferation, and gene transcription. CXCR4, initially discovered for its involvement in HIV entry and leukocytes trafficking, is overexpressed in more than 23 human cancers. Cancer cell CXCR4 overexpression contributes to tumor growth, invasion, angiogenesis, metastasis, relapse, and therapeutic resistance. CXCR4 antagonism has been shown to disrupt tumor–stromal interactions, sensitize cancer cells to cytotoxic drugs, and reduce tumor growth and metastatic burden. As such, CXCR4 is a target not only for therapeutic intervention but also for noninvasive monitoring of disease progression and therapeutic guidance. This review provides a comprehensive overview of the biological involvement of CXCR4 in human cancers, the current status of CXCR4-based therapeutic approaches, as well as recent advances in noninvasive imaging of CXCR4 expression.

show abstract

Section: Role Of Cxcr4 In Cancermentioning

confidence: 99%

The Intricate Role of CXCR4 in Cancer

Chatterjee

Azad

Nimmagadda

2014

Advances in Cancer Research

551

546

View full text Add to dashboard Cite

show abstract

“…It is the second most common type of hematological malignancy in the Western world. 115 According to an NCI report, 22,350 new cases and 10,710 deaths are estimated to occur in 2013 in the United States due to this disease.…”

Section: Multiple Myelomamentioning

confidence: 99%

Cancer Preventive and Therapeutic Properties of Fruits and Vegetables Against Commonly Occurring Cancers in Humans

Monisha¹,

Bakliwal²,

Katre³

et al. 2015

Anticancer Properties of Fruits and Vegetables

View full text Add to dashboard Cite

“…Plain X‐ray assessment is of limited use in assessing treatment response and in monitoring, as lytic bone lesions seldom show evidence of healing on plain X‐rays (Wahlin et al , ). Its role is more restricted to helping define progressive disease by providing evidence of new bone lesions but caution is needed, as new vertebral compression fractures on plain X‐rays do not necessarily signify disease progression and may represent structural weakness (Collins, ).…”

Section: Use Of Imaging In the Assessment Of Treatment Response And Dmentioning

confidence: 99%

Guidelines for the use of imaging in the management of patients with myeloma

et al. 2017

View full text Add to dashboard Cite

Summary The role of imaging in myeloma has gained increasing importance over the past few years. The recently revised definition of myeloma from the International Myeloma Working Group (IMWG) includes cross sectional imaging as a method to define bone disease and also incorporates its use in the disease definition for patients with suspected smouldering myeloma. The National Institute for Health and Care Excellence myeloma guidelines also recommend cross sectional imaging for patients with suspected myeloma. There is also increasing use of imaging in disease assessments and the International Myeloma Working Group has recently incorporated imaging in defining new response categories of minimal residual disease negativity, with or without imaging‐based evidence of disease. Plain X‐rays have previously been the standard imaging modality included in a myeloma work up at presentation but evidence is mounting for use of cross‐sectional modalities such as computed tomography (CT), magnetic resonance imaging (MRI) and 18fluoro‐deoxyglucose (18F‐FDG) positron emission tomography (PET)/CT. Funding and therefore availability of newer imaging techniques remains a barrier. Here, we propose an evidence‐based approach to the use and technical application of the latest imaging modalities at diagnosis and in the follow‐up of patients with myeloma and plasmacytoma.

show abstract

Problems monitoring response in multiple myeloma

Abstract: There has been a revolution in the treatment of multiple myeloma over the past decade. This article seeks to correlate advances in imaging with advances in treatment and to highlight how proper understanding of both is necessary for optimum management.

Cited by 28 publications

References 87 publications

The Intricate Role of CXCR4 in Cancer

The Intricate Role of CXCR4 in Cancer

Cancer Preventive and Therapeutic Properties of Fruits and Vegetables Against Commonly Occurring Cancers in Humans

Guidelines for the use of imaging in the management of patients with myeloma

Contact Info

Product

Resources

About